A major challenge facing both HTA authorities and manufacturers is integrating new and innovative treatments into the healthcare system. A new article from Xcenda explores pathways to market for state-of-the-art treatments and advanced therapy medicinal products (ATMPs) in the German context. In this context, exceptions must often be made to standard procedure. Read more here.
(Source: Ulrike Kuchenbecker, PhD; Xcenda; 11/2/20)